Incidence and Costs of Cervical Intraepithelial Neoplasia in a US Commercially Insured Population
- 1 January 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Lower Genital Tract Disease
- Vol. 14 (1), 29-36
- https://doi.org/10.1097/lgt.0b013e3181ac05e9
Abstract
This study aimed to estimate incidence, cost per episode of care, and US population burden of cervical intraepithelial neoplasia (CIN). For women continuously enrolled in a US health plan from January 1, 1999 to December 31, 2004, medical claims were used to identify potential CIN diagnosis. Presence and grade of CIN (CIN 1, CIN 2,3, or no CIN) were verified in medical records for a randomly selected subset (n = 254). Incidence, costs, and population burden were calculated. Annual incidence for CIN 1 and CIN 2,3 was 1.6 and 1.2 per 1,000 women, respectively. Incidence was highest among women aged 21 to 30 years (3.3 and 3.6 per 1,000) and women aged 31 to 40 years (2.9 and 2.7 per 1,000). Costs per episode of care were higher for CIN 2,3 ($1,634 vs $1,084). Estimated annual burden per 1,000 US women was $1,059 for CIN 1 and $1,803 for CIN 2,3. We estimate that 412,000 women in the United States are diagnosed with CIN annually, with an associated cost of approximately $570 million.Keywords
This publication has 14 references indexed in Scilit:
- Cost-effectiveness analyses of human papillomavirus vaccinationThe Lancet Infectious Diseases, 2007
- Prevalence of HPV Infection Among Females in the United StatesJama-Journal Of The American Medical Association, 2007
- Mathematical Models for Predicting the Epidemiologic and Economic Impact of Vaccination against Human Papillomavirus Infection and DiseaseEpidemiologic Reviews, 2006
- Prophylactic HPV vaccines: Reducing the burden of HPV-related diseasesVaccine, 2006
- The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?Current Opinion in Obstetrics and Gynecology, 2006
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Diagnoses and outcomes in cervical cancer screening: A population-based studyAmerican Journal of Obstetrics and Gynecology, 2004
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Evaluation of Human Papillomavirus Testing in Primary Screening for Cervical AbnormalitiesPublished by American Medical Association (AMA) ,2002
- Frequency of Cervical Smear Abnormalities Within 3 Years of Normal CytologyObstetrics & Gynecology, 2000